Stocks of Teleflex Incorporated (NYSE:TFX) traded higher last session on Wall Street, up 4.01% to $225.71.
According to the data, Teleflex Incorporated (NYSE:TFX) has 16 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $330.00 and a low of $215.00, we find $231.00. Given the previous closing price of $217.00, this indicates a potential upside of 6.45 percent. TFX stock price is now 8.66% away from the 50-day moving average and -15.47% away from the 200-day moving average. The market capitalization of the company currently stands at $10.41B.
A total of 10 analysts have issued a hold rating and 5 have given it a buy rating. Brokers who have rated the stock have averaged $250.77 as their price target over the next twelve months.
With the price target of $220, Mizuho recently initiated with Neutral rating for Teleflex Incorporated (NYSE: TFX)., while ‘Jefferies’ rates the stock as ‘Hold’.
In other news, RANDLE STUART A, Director sold 3,014 shares of the company’s stock on Jun 07. The stock was sold for $853,896 at an average price of $283.31. Upon completion of the transaction, the Director now directly owns 4,320 shares in the company, valued at $0.98 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 27, Chairman, President & CEO Kelly Liam sold 8,987 shares of the business’s stock. A total of $2,965,710 was realized by selling the stock at an average price of $330.00. This leaves the insider owning 25,775 shares of the company worth $5.82 million. Insiders disposed of 14,679 shares of company stock worth roughly $3.31 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TFX stock. A new stake in Teleflex Incorporated shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $1,907,719,000. BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. invested $19,109,000 in shares of TFX during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in Teleflex Incorporated valued at approximately $9,313,000. SELECT EQUITY GROUP, L.P. acquired a new stake in TFX for approximately $8,757,000. DNB ASSET MANAGEMENT AS purchased a new stake in TFX valued at around $4,614,000 in the second quarter. In total, there are 778 active investors with 97.50% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $217.61 for Teleflex Incorporated (NYSE: TFX). During the past 12 months, Teleflex Incorporated has had a low of $182.65 and a high of $356.72. As of last week, the company has a debt-to-equity ratio of 0.44, a current ratio of 2.40, and a quick ratio of 1.50. The fifty day moving average price for TFX is $207.47 and a two-hundred day moving average price translates $266.54 for the stock.
The latest earnings results from Teleflex Incorporated (NYSE: TFX) was released for Sep, 2022. According to the Medical Instruments & Supplies Company, earnings per share came in at $3.27, beating analysts’ expectations of $3.11 by 0.16. This compares to -$0.01 EPS in the same period last year. The net profit margin was 14.80% and return on equity was 10.80% for TFX. The company reported revenue of $686.79 million for the quarter, compared to $700.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.92 percent. For the current quarter, analysts expect TFX to generate $763.39M in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/15/2022. Investors who held shares on 11/15/2022 were paid a $0.34 dividend. On an annualized basis, this represents a $1.36 dividend and a 0.60% percent yield. There was an ex-dividend date of 11/14/2022 for this dividend. In terms of dividend payout ratio, TFX is presently at 15.50%.
Teleflex Incorporated(TFX) Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.